



P Dubsy

Kontakt

P Dubsy

Publikationen (13)

Burstein H, Thürlimann B, Winer E, Senn H, Regan M, Piccart-Gebhart M, Denkert C, Colleoni M, Poortmans P, Gnant M, Dubsy P, Loibl S, Curigliano G, Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. *Ann Oncol* 2019; 30:1541-1557.

Curigliano G, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsy P, Gnant M, P Winer E, Burstein H, Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017. Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017". *Ann Oncol* 2019; 30:1181.

Burstein H, Thürlimann B, Winer E, Senn H, Regan M, Piccart-Gebhart M, Denkert C, Colleoni M, Poortmans P, Gnant M, Dubsy P, Loibl S, Curigliano G, Members of the St. Gallen International Consensus Panel on the Primary Therapy of Early Breast Cancer 2019. Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. *Ann Oncol* 2019; 30:1541-1557.

Curigliano G, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsy P, Gnant M, P Winer E, Burstein H, Panel Members of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Ann Oncol* 2019; 30:1181.

Xu B, Osborne K, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Khaled H, Huober J, Huang C, Hayes D, Harbeck N, Pagani O, Partridge A, Pritchard K, Whelan T, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E, Ro J, Goodwin P, Gulluoglu B, André F, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsy P, Gnant M, Winer E, Burstein H, Baselga J, Bergh J, Bonnefoi H, Garber J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Brucker S, Curigliano G. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Ann Oncol* 2018; 29:2153.

Xu B, Osborne K, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Khaled H, Huober J, Huang C, Hayes D, Harbeck N, Pagani O, Partridge A, Pritchard K, Whelan T, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsy P, Gnant M, Winer E, Burstein H, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Brucker S, Bonnefoi H, Curigliano G. Reply to "The St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology" by Kirova et al. *Ann Oncol* 2017

Xu B, Osborne K, Orecchia R, Morrow M, Karlsson P, Jiang Z, Jassem J, Hussein K, Huober J, Huang C, Hayes D, Harbeck N, Pagani O, Partridge A, Pritchard K, Whelan T, Watanabe T, Viale G, Tutt A, Toi M, Smith I, Shao Z, Semiglazov V, Sedlmayer F, Rutgers E, Ro J, Goodwin P, Gulluoglu B, Garber J, Thürlimann B, Senn H, Piccart-Gebhart M, Regan M, Colleoni M, Loibl S, Dubsy P, Gnant M, P Winer E, Burstein H, André F, Baselga J, Bergh J, Galimberti V, Francis P, Ejlertsen B, Di Leo A, Denkert C, Cuzick J, Ciruelos E, Carey L, Cardoso F, Y Brucker S, Bonnefoi H, Curigliano G. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. *Ann Oncol* 2017; 28:1700-1712.

von Minckwitz G, Jackisch C, Kümmel S, Fasching P, Schneeweiss A, Paepke S, Untch M, Burchardi N, Mehta K, Loibl S, Hanusch C, Denkert C, Rezai M, Tesch H, Huober J, Gerber B, Zahm D, Hilfrich J, Costa S, Dubsy P, Blohmer J, German Breast Group and Austrian Breast and Colon Cancer Study Group Investigators. Zoledronate for patients with invasive residual disease after anthracyclines-taxane-based chemotherapy for early breast cancer - The Phase III NeoAdjuvant Trial Add-on (NaTaN) study (GBG 36/ABCSG 29). *Eur J Cancer* 2016; 64:12-21.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG), Kaufmann M, Kilburn L, Perrone F, Rea D, Thürlimann B, van de Velde C, Pan H, Peto R, Davies C, Gnant M, Dubsy P, Cuzick J, Dowsett M, Forbes J, Bradley R, Ingle J, Aihara T, Bliss J, Boccardo F, Coates A, Coombes R, Gray R. Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. *Lancet* 2015; 386:1341-52.

Gnant M, Kwasny W, Dubsy P, Selim U, Fitzal F, Hochreiner G, Wette V, Sevelde P, Ploner F, Bartsch R, Fesl C, Greil R, Steger G, Eiermann W, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Knauer M, Moik M, Jakesz R, Seifert M, Taucher S, Bjelic-Radusic V, Balic M, Eidtmann H, Austrian Breast and Colorectal Cancer Study Group, Vienna, Austria. Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12. *Ann Oncol* 2014; 26:313-20.

Gnant M, Steger G, Balic M, Ressler S, Cowens J, Storhoff J, Ferree S, Schaper C, Liu S, Fesl C, Nielsen T, Bartsch R, Fitzal F, Dubsy P, Filipits M, Greil R, Stoeger H, Rudas M, Bago-Horvath Z, Mlineritsch B, Kwasny W, Knauer M, Singer C, Jakesz R, Austrian Breast and Colorectal Cancer Study Group. Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. *Ann Oncol* 2013; 25:339-45.

Berghoff A, Preusser M, Steger G, Zielinski C, Gnant M, Mader R, Dieckmann K, Fitzal F, Eiter H, Knauer M, Rottenfusser A, Rudas M, Pluschnig U, Dubsy P, De Vries C, Bago-Horvath Z, Bartsch R. Brain metastases free survival differs between breast cancer subtypes. *Br J Cancer* 2012; 106:440-6.

Jakesz R, Dubsy P, Eidtmann H, Schem C, Lang A, Thürlimann B. Neue Erkenntnisse vom SABCS, Expert Discussion. *Breast Care* 2009; 4:55-60.

Projekte (0)

Keine Resultate gefunden.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch